166 related articles for article (PubMed ID: 37649029)
1. Diagnostic dilemma in a patient with history of medullary thyroid carcinoma and abnormal serum liver enzymes; a case report with six years follow up.
Rahmani F; Tohidi M; Azmoudeh-Ardalan F; Sadeghi A; Hadaegh F
BMC Endocr Disord; 2023 Aug; 23(1):186. PubMed ID: 37649029
[TBL] [Abstract][Full Text] [Related]
2. Multiple Endocrine Neoplasia Type 2B Associated Mixed Medullary and Follicular Thyroid Carcinoma in A Chinese Patient with RET M918T Germline Mutation.
Qi XP; Lin GB; Chen B; Li F; Cao ZL; Zheng WH; Zhao JQ
Endocr Metab Immune Disord Drug Targets; 2021; 21(3):554-560. PubMed ID: 32660411
[TBL] [Abstract][Full Text] [Related]
3. Optimizing Diagnostic Accuracy of Fine Needle Aspiration Biopsy Calcitonin Measurements in Detecting Medullary Thyroid Carcinoma.
Cavallo AC; Pitoia F; Roberti J; Brenzoni P; Lencioni M; Jaroslavsky MJ; Spengler E; Voogd A; Firpo C; Saco P; Piñero F; Negueruela M
Thyroid; 2024 Feb; 34(2):186-196. PubMed ID: 38047535
[No Abstract] [Full Text] [Related]
4. Management of thyroid cancer: United Kingdom National Multidisciplinary Guidelines.
Mitchell AL; Gandhi A; Scott-Coombes D; Perros P
J Laryngol Otol; 2016 May; 130(S2):S150-S160. PubMed ID: 27841128
[TBL] [Abstract][Full Text] [Related]
5. Medullary Thyroid Carcinoma With Elevated Serum CEA and Normal Serum Calcitonin After Surgery: A Case Report and Literature Review.
Chen L; Zhao K; Li F; He X
Front Oncol; 2020; 10():526716. PubMed ID: 33194586
[TBL] [Abstract][Full Text] [Related]
6. High CEA levels in a case of resected colorectal cancer: delayed diagnosis of metachronous medullary thyroid cancer.
Chen SW; Chen YK
World J Surg Oncol; 2017 Dec; 15(1):230. PubMed ID: 29284496
[TBL] [Abstract][Full Text] [Related]
7. Combining serum calcitonin, carcinoembryonic antigen, and neuron-specific enolase to predict lateral lymph node metastasis in medullary thyroid carcinoma.
Ye L; Zhou X; Lu J; Wang Y; Xie X; Zhang J
J Clin Lab Anal; 2020 Jul; 34(7):e23278. PubMed ID: 32141647
[TBL] [Abstract][Full Text] [Related]
8. Calcitonin-negative neuroendocrine tumor of the thyroid: a distinct clinical entity.
Chernyavsky VS; Farghani S; Davidov T; Ma L; Barnard N; Amorosa LF; Trooskin SZ
Thyroid; 2011 Feb; 21(2):193-6. PubMed ID: 21275766
[TBL] [Abstract][Full Text] [Related]
9. Long-Term Follow-up in Medullary Thyroid Carcinoma.
Raue F; Frank-Raue K
Recent Results Cancer Res; 2015; 204():207-25. PubMed ID: 26494391
[TBL] [Abstract][Full Text] [Related]
10. Brain metastasis from calcitonin-negative medullary thyroid carcinoma.
Baptista PF; Fonseca LCM; Carvalho AFC; Silva SNVD; Freitas CRO
Ann Endocrinol (Paris); 2022 Aug; 83(4):258-260. PubMed ID: 35537523
[TBL] [Abstract][Full Text] [Related]
11. Concomitant medullary thyroid carcinoma with paraganglioma-like pattern and papillary thyroid carcinoma.
Greco C; Brigante G; Taliani E; Corrado S; Simoni M; Madeo B
Endocrinol Diabetes Metab Case Rep; 2019 Nov; 2019():. PubMed ID: 31778356
[TBL] [Abstract][Full Text] [Related]
12. Epidemiology and Clinical Presentation of Medullary Thyroid Carcinoma.
Raue F; Frank-Raue K
Recent Results Cancer Res; 2015; 204():61-90. PubMed ID: 26494384
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic value of selected biochemical markers in the detection of recurrence of medullary thyroid cancer - comparison of calcitonin, procalcitonin, chromogranin A, and carcinoembryonic antigen.
Woliński K; Kaznowski J; Klimowicz A; Maciejewski A; Łapińska-Cwojdzińska D; Gurgul E; Car AD; Fichna M; Gut P; Gryczyńska M; Ruchała M
Endokrynol Pol; 2017; 68(4):434-437. PubMed ID: 28585679
[TBL] [Abstract][Full Text] [Related]
14. Intermixed medullary and papillary thyroid cancer in a patient with renal cell carcinoma.
Samarasinghe S; Yuksel S; Mehrotra S
Endocrinol Diabetes Metab Case Rep; 2020 Jun; 2020():. PubMed ID: 32538376
[TBL] [Abstract][Full Text] [Related]
15. An Unusual Case of Medullary Thyroid Carcinoma and A Revision of Current Literature.
Cipri C; Vescini F; Torresan F; Pennelli G; Pelizzo MR; Triggiani V; Guastamacchia E; Grimaldi F
Endocr Metab Immune Disord Drug Targets; 2019; 19(2):226-229. PubMed ID: 30574858
[TBL] [Abstract][Full Text] [Related]
16. Medullary thyroid cancer with undetectable serum calcitonin.
Brutsaert EF; Gersten AJ; Tassler AB; Surks MI
J Clin Endocrinol Metab; 2015 Feb; 100(2):337-41. PubMed ID: 25490273
[TBL] [Abstract][Full Text] [Related]
17. Usefulness of Serum Calcitonin in Patients Without a Suspicious History of Medullary Thyroid Carcinoma and with Thyroid Nodules Without an Indication for Fine-Needle Aspiration or with Benign Cytology.
Rosario PW; Calsolari MR
Horm Metab Res; 2016 Jun; 48(6):372-276. PubMed ID: 27203410
[TBL] [Abstract][Full Text] [Related]
18. Case Report: A Challenging Clinical Problem of Calcitonin-Negative Medullary Thyroid Cancer Diagnosis and Surveillance.
Rafaey W; Munir Alvi A; Siddiqi AI; Shafiq W; Irfan H
Cureus; 2022 Nov; 14(11):e32088. PubMed ID: 36600874
[TBL] [Abstract][Full Text] [Related]
19. Usefulness of Serum Calcitonin in Patients with Thyroid Nodules ≤ 1 cm Without an Indication for Fine-Needle Aspiration.
Rosario PW; Mourão GF; Calsolari MR
Horm Metab Res; 2020 Apr; 52(4):216-219. PubMed ID: 32168524
[TBL] [Abstract][Full Text] [Related]
20. Diagnosis and pathologic characteristics of medullary thyroid carcinoma-review of current guidelines.
Thomas CM; Asa SL; Ezzat S; Sawka AM; Goldstein D
Curr Oncol; 2019 Oct; 26(5):338-344. PubMed ID: 31708652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
